Sugi Predict

Sugi Predict / Compounds / SCHEMBL553963

SCHEMBL553963

SCHEMBL553963

CNCCO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTR1B P28222 3/20 0.46
▸ HTR1D P28221 2/20 0.46
▸ HTT P42858 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ SMYD2 Q9NRG4 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ TAAR1 Q96RJ0 2/20 0.37
▸ ATM Q13315 1/20 0.37
▸ CHRNB2 P17787 1/20 0.36
▸ CHRNA4 P43681 1/20 0.36
▸ LMNA P02545 2/20 0.36
▸ HTR2A P28223 1/20 0.35
▸ HRH1 P35367 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5724577 0.95 HTR1B (0.42) HTR1BHTR1DHTTCYP3A4SMN1; SMN2
SCHEMBL28931474 0.91 HTR1B (0.41) HTR1BHTR1DHTTCYP3A4SMN1; SMN2
SCHEMBL26650967 0.90 HTR1B (0.50) HTR1BHTR1DHTTCYP3A4SMN1; SMN2
SCHEMBL31691748 0.89 LMNA (0.46) HTR1BHTR1DHTTCYP3A4SMN1; SMN2
SCHEMBL554231 0.88 HTT (0.41) HTTCYP3A4SMN1; SMN2GAASMYD2
SCHEMBL21878235 0.85 CYP3A4 (0.40) HTR1BHTR1DHTTCYP3A4SMN1; SMN2
SCHEMBL18286159 0.85 ALDH1A1 (0.41) HTTCYP3A4SMN1; SMN2KDM4EALDH1A1
SCHEMBL553453 0.83 HTT (0.51) HTR1BHTTCYP3A4SMN1; SMN2GAA
SCHEMBL3682390 0.83 MAPT (0.41) HTTCYP3A4SMN1; SMN2ALDH1A1SMYD2
SCHEMBL19972614 0.82 CYP3A4 (0.41) HTR1BHTTCYP3A4SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4640668-A1 LIPID COMPOUND, LIPID NANOPARTICLE COMPRISING SAME AND USE THEREOF TheMedium Therapeutics Co., Ltd. (CN) 2025-10-29 — — EP disclosed
US-20250325490-A1 LIPID COMPOUND, LIPID NANOPARTICLE COMPRISING SAME AND USE THEREOF THEMEDIUM THERAPEUTICS CO LTD (CN) 2025-10-23 — — US disclosed
CN-118084714-B Lipid compound, lipid nanoparticle containing lipid compound and application of lipid compound 传信生物医药(苏州)有限公司 2024-08-02 — — CN disclosed
EP-3480224-B1 ELECTRO-OPTIC POLYMER NAT INST INF & COMM TECH (JP) 2024-06-12 — — EP disclosed
CN-109415468-B Electro-optical polymers 国立研究开发法人情报通信研究机构 2024-06-07 — — CN disclosed
CN-118084714-A Lipid compound, lipid nanoparticle containing lipid compound and application of lipid compound 传信生物医药(苏州)有限公司 2024-05-28 — — CN disclosed
CN-116332910-A 2-aminopyrimidine derivatives as kinase inhibitors, preparation and use thereof 江苏威凯尔医药科技有限公司 2023-06-27 — — CN disclosed
WO-2023106062-A1 ELECTRO-OPTIC FILM, COMPOUND, ELECTRO-OPTIC COMPOSITION, AND ELECTRO-OPTIC ELEMENT 住友化学株式会社 2023-06-15 — — WO disclosed
US-20220380370-A1 XANTHINE CB1 INHIBITORS GFB (ABC), LLC 2022-12-01 — — US disclosed
EP-4034101-A1 XANTHINE CB1 INHIBITORS Goldfinch Bio, Inc. (US) 2022-08-03 — — EP disclosed
EP-0783482-B1 CATIONIC TRANSPORT REAGENTS UNIV CALIFORNIA (US) 2003-07-30 — — EP disclosed
EP-0622361-B1 Heterocyclic compounds as bradykinin antagonists FUJISAWA PHARMACEUTICAL CO (JP) 2001-10-04 — — EP disclosed
US-6169095-B1 FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES IN THE EYE, SUCH AS ALLERGY, INFLAMMATION AND PAIN OF THE EYE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 — — US disclosed
US-5922711-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES, SHOCK OR ANALGESICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-07-13 — — US disclosed
US-5892071-A TRANSPORTATION OF ACTIVE SPECIES INTO MEMBRANE BARRIERS THE REAGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-04-06 — — US disclosed
US-5744625-A CATIONIC DIAMINE FOR TRANSPORTING BIOLOGICALLY ACTIVE SPECIES INTO AND THROUGH MEMBRANE BARRIERS THE REAGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-04-28 — — US disclosed
US-5708173-A PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-01-13 — — US disclosed
US-5563162-A CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-10-08 — — US disclosed
US-5527928-A USED FOR TRANSPORTING BIOLOGICALLY ACTIVE SPECIES INTO AND THROUGH MEMBRANE BARRIERS REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE 1996-06-18 — — US disclosed
EP-0622361-A1 Heterocyclic compounds as bradykinin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-11-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380370-A1 XANTHINE CB1 INHIBITORS CNR1, GPR119, CNR2 HTR1B 403/4885HTR1D 383/4885HTT 4795/4885
US-20250325490-A1 LIPID COMPOUND, LIPID NANOPARTICLE COMPRISING SAME AND USE THEREOF PNLIP, LIPC, FABP2 HTR1B 4803/4885HTR1D 4866/4885HTT 3613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.